Taylor Frigon Capital Management LLC lessened its stake in ResMed Inc. (NYSE:RMD) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,402 shares of the medical equipment provider’s stock after selling 194 shares during the quarter. ResMed comprises 1.5% of Taylor Frigon Capital Management LLC’s investment portfolio, making the stock its 20th biggest position. Taylor Frigon Capital Management LLC’s holdings in ResMed were worth $2,232,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Voya Investment Management LLC grew its position in ResMed by 0.6% in the third quarter. Voya Investment Management LLC now owns 80,431 shares of the medical equipment provider’s stock valued at $10,867,000 after acquiring an additional 452 shares during the last quarter. Voloridge Investment Management LLC grew its position in ResMed by 748.7% in the third quarter. Voloridge Investment Management LLC now owns 64,316 shares of the medical equipment provider’s stock valued at $8,690,000 after acquiring an additional 56,738 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in ResMed by 3.5% in the third quarter. Public Employees Retirement System of Ohio now owns 57,728 shares of the medical equipment provider’s stock valued at $7,800,000 after acquiring an additional 1,971 shares during the last quarter. California State Teachers Retirement System grew its position in ResMed by 1.1% in the third quarter. California State Teachers Retirement System now owns 260,475 shares of the medical equipment provider’s stock valued at $35,193,000 after acquiring an additional 2,948 shares during the last quarter. Finally, Man Group plc grew its position in ResMed by 149.8% in the third quarter. Man Group plc now owns 92,624 shares of the medical equipment provider’s stock valued at $12,515,000 after acquiring an additional 55,543 shares during the last quarter. 66.52% of the stock is owned by institutional investors and hedge funds.

In related news, COO Robert Andrew Douglas sold 1,264 shares of ResMed stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $158.43, for a total value of $200,255.52. Following the transaction, the chief operating officer now directly owns 66,671 shares of the company’s stock, valued at $10,562,686.53. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rajwant Sodhi sold 1,350 shares of ResMed stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $144.38, for a total value of $194,913.00. Over the last ninety days, insiders sold 60,653 shares of company stock worth $9,035,942. 1.22% of the stock is owned by insiders.

Shares of ResMed stock traded up $0.77 during midday trading on Friday, reaching $162.16. The company had a trading volume of 23,787 shares, compared to its average volume of 374,182. The stock has a fifty day moving average price of $155.96 and a 200 day moving average price of $140.56. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.11 and a quick ratio of 1.46. The firm has a market cap of $23.64 billion, a PE ratio of 55.97, a P/E/G ratio of 3.44 and a beta of 0.42. ResMed Inc. has a fifty-two week low of $90.64 and a fifty-two week high of $165.00.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.06. The company had revenue of $681.06 million for the quarter, compared to analyst estimates of $660.87 million. ResMed had a return on equity of 26.72% and a net margin of 15.52%. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.81 earnings per share. As a group, sell-side analysts forecast that ResMed Inc. will post 4.11 EPS for the current year.

A number of research analysts have issued reports on RMD shares. KeyCorp began coverage on ResMed in a research report on Friday, November 22nd. They issued a “sector weight” rating on the stock. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Friday, October 25th. ValuEngine cut ResMed from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Oppenheimer began coverage on ResMed in a report on Thursday, January 9th. They set a “hold” rating on the stock. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. ResMed has an average rating of “Buy” and an average target price of $121.50.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

Read More: What is a Buy-Side Analyst?

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.